You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
According to a US Food and Drug Administration webinar yesterday, a lot of IDT test kits has been qualified by CDC and is authorized for purchase.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
The group will integrate IDT's oligo synthesis technology with 3CR's PCR Allele Competitive Extension (PACE) Genotyping Master Mix and expertise in developing assays.
IDT and Beijing-based ChosenMed plan to develop large pan-cancer panels as part of the Cancer Genome Atlas of China.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.
CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.